Drugs / TS-161
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03919409 | Jun 2019 → Feb 2020 | — | Taisho Pharmaceutical R&D Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04821271 | Jun 2021 → May 2024 | major depressive disorder | National Institute of Mental Health (NIMH) | Terminated | Missed primary Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TS-161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04821271 ↗ |
| Action | Inhibit | “TS-161 is a mGlu2/3 receptor antagonist prodrug.” NCT04821271 ↗ |
| Route | Oral | “TS-161 Administered Orally” NCT03919409 ↗ |